Saturday 17 October 2026 Export NUTX’s income statement to Excel — free account

Nutex Health Inc.

Nutex Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $875.3 million, up 82.4% from fiscal 2024. In the quarter to June 2026, revenue fell 13.6%, EPS grew 424.8%, free cash flow grew 19.4% and total debt fell 1.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

185.95 14.85 −7.40%

Follow NUTX

Alert me

Market cap: $1.4B
P/E: 7.1×
Fwd P/E: 6.3×
Dividend yield: —
F-score: 7/9
Altman Z: 3.27
Beneish M: −2.54
Dividend safety: 41/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.15

Total sells 0.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	4	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	1	—

Insider Ownership 33.05%

Capital & Financial Ratios $m

Market Cap 1,380.00

Revenue 846.72

Net Income 272.49

Free Cash Flow 274.17

Net Debt 93.00

Current Ratio 5.00

Debt/Equity 0.59

P/E ratio 7.14

Fwd P/E 6.25

P/S ratio 1.51

P/B ratio 2.52

Past 5Y EPS Growth (22.22%)

This Y EPS Growth 165.21%

Next Y EPS Growth 0.28%

Next Y revenue growth (0.37%)

Next 5Y EPS Growth 34.22%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 69.89%

10-year low 10-year high

P/B against its own 10 years 62.51%

10-year low 10-year high

EV/Sales against its own 10 years 55.66%

10-year low 10-year high

EV/FCF against its own 10 years 17.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	22	44	186	207
Receivables	63	236	325	357
Inventory	3	3	3	4
Other	—	—	—	—
	91	292	539	586

	2023	2024	2025	Q'26
Payables	25	10	49	10
ST’ Debt	14	18	14	0
Other	—	—	—	—
	58	154	158	117

Compound Annual Growth %

	10y	5y	3y
Sales	—	26.14%	58.62%
Cash Flow	—	23.41%	69.88%
Earnings	—	(7.75%)	0.00%
Book Value	—	0.00%	52.10%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	216	211	—	—	—
’25	212	244	268	152	875
’24	67	76	79	258	480
’23	56	59	63	70	248
’22	79	58	28	54	219
’21	2	63	118	149	332
’20	0	0	0	273	274

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	76	34	—	—	—
’25	51	27	100	70	248
’24	3	13	7	0	23
’23	1	0	2	(2)	1
’22	36	18	(7)	5	51
’21	(1)	103	24	46	173
’20	(1)	0	0	88	87

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	74	32	—	—	—
’25	51	27	99	69	246
’24	2	13	6	0	21
’23	(3)	(3)	(1)	(1)	(8)
’22	27	10	(13)	12	36
’21	(1)	82	21	35	137
’20	(1)	0	0	27	25

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	6.52	9.58	—	—	—
’25	2.56	(2.95)	7.76	1.61	10.48
’24	(0.10)	(0.07)	(1.72)	11.12	9.71
’23	(1.50)	(0.97)	(1.50)	(7.50)	(10.49)
’22	6.28	(4.50)	(97.45)	(3.00)	(100.45)
’21	(36.20)	7.51	18.84	52.48	42.62
’20	(35.98)	7.33	50.83	14.86	36.81

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	75.00	25.50	4.16	28.82	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	7,920.00	318.00	41.44	193.07
People
People	Employees	18	6	6	12	14	24	1,150	800	800	944
	Revenue/emp, $m	0.00	0.00	0.23	0.11	19.57	13.81	0.19	0.31	0.60	0.93
Income, $m
Income, $m	Revenue	—	0	1	1	274	332	219	248	480	875
	Gross margin, %	—	(31.47)	62.87	39.23	57.51	54.08	7.03	14.04	40.89	50.76
	EBT	0	(6)	(1)	(7)	146	169	(420)	(48)	110	245
	EBT margin, %	0.00	(25,894.40)	(69.50)	(520.82)	53.18	51.12	(191.36)	(19.58)	22.88	27.97
	Net income	(7)	1	(1)	(7)	146	169	(433)	(43)	95	180
	Depreciation	0	1	0	0	6	8	13	18	19	21
Per share, $
Per share, $	Revenue	0.00	21.09	119.91	56.46	69.31	83.85	51.81	56.18	94.28	137.59
	Earnings	(14,038.98)	364.70	(83.67)	(230.61)	(179.63)	(48.94)	(100.45)	(10.49)	10.25	11.13
	Cash flow	(548.40)	(649.64)	(42.11)	(166.97)	21.92	43.86	11.96	0.29	4.55	39.00
	Capex	0.00	0.00	0.00	(3.47)	(15.48)	(9.34)	(3.46)	(2.15)	(0.45)	(0.40)
	Free cash flow	(548.40)	(649.64)	(42.11)	(170.44)	6.45	34.52	8.50	(1.87)	4.10	38.61
	Book value	(11,738.80)	2,153.64	(131.35)	76.79	(0.29)	48.45	28.43	17.94	37.03	66.56
	Shares, m	0	0	0	0	4	4	4	4	5	6
Valuation, ×
Valuation, ×	P/E	—	70.50	70.50	70.50	70.50	70.50	0.00	0.00	3.19	17.38
	P/S	—	58.05	58.05	58.05	58.05	58.05	5.76	0.53	0.34	1.20
	P/B	—	328.93	328.93	328.93	328.93	328.93	10.50	1.67	0.86	2.47
	EV/Sales	—	58.03	58.03	58.03	58.03	58.03	6.71	1.47	0.87	1.33
	EV/FCF	—	144.40	144.40	144.40	144.40	144.40	40.89	(44.25)	20.03	4.72
Cash, $m
Cash, $m	Operating cash flow	0	(1)	0	(4)	87	173	51	1	23	248
	Capex	—	—	—	0	(61)	(37)	(15)	(9)	(2)	(3)
	Free cash flow	0	(1)	0	(4)	25	137	36	(8)	21	246
Balance, $m
Balance, $m	Working capital	(6)	(1)	(1)	(3)	(1)	116	43	33	138	381
	Total debt	0	0	1	2	0	155	242	254	300	312
	Net debt	0	0	1	1	0	119	208	232	256	126
	Shareholders’ equity	(6)	2	(1)	2	(1)	192	120	79	189	423
Returns, %
Returns, %	ROA	(2,910.02)	30.32	(50.29)	(199.29)	3,088.42	67.17	(102.80)	(11.03)	9.89	9.00
	ROIC	0.00	(132.11)	0.00	(137.79)	0.00	34.30	(77.50)	(6.38)	18.36	31.34
	ROE	0.00	(33.26)	(218.01)	(3,942.66)	29,249.21	139.24	(272.38)	(45.92)	38.93	23.13

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARDT Ardent Health, Inc.	$1.7B	21.7×	7.7×	−1.40% (below 0%: shrinking)	−76.92% (below 0%: shrinking)	+121.70% (above 0%: growing)	100.00%	3.44%	Compare
CMPS COMPASS Pathways PLC Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−4.18% (below 0%: shrinking)	—	0.00%	Compare
AMN AMN Healthcare Services Inc	$1.6B	15.0×	31.2×	+2.29% (above 0%: growing)	n/m	−389.43% (below 0%: shrinking)	30.58%	4.00%	Compare
AGL Agilon Health, Inc.	$1.5B	— (loss-making)	— (loss-making)	+7.15% (above 0%: growing)	n/m	−50.19% (below 0%: shrinking)	7.17%	0.79%	Compare
PNTG The Pennant Group, Inc.	$1.5B	44.5×	26.9×	+35.76% (above 0%: growing)	+23.81% (above 0%: growing)	−50.94% (below 0%: shrinking)	14.07%	5.77%	Compare
HCSG Healthcare Services Group, Inc.	$1.5B	12.2×	19.2×	+2.69% (above 0%: growing)	n/m	−26.02% (below 0%: shrinking)	15.89%	4.72%	Compare
NUTX Nutex Health Inc.	$1.4B	7.1×	6.3×	−13.62% (below 0%: shrinking)	n/m	+19.44% (above 0%: growing)	67.04%	57.75%
USPH U.S. Physical Therapy, Inc.	$1.3B	504×	27.7×	+8.47% (above 0%: growing)	−56.90% (below 0%: shrinking)	−8.24% (below 0%: shrinking)	19.59%	10.25%	Compare
INNV InnovAge Holding Corp.	$1.2B	— (loss-making)	17.2×	+18.31% (above 0%: growing)	n/m	+85.44% (above 0%: growing)	23.88%	3.87%	Compare
Median of peers	$1.5B	21.7×	23.0×	+7.15%	−56.90%	−17.13%	19.59%	3.93%

All 55 Medical Care Facilities stocks →

Nutex Health Inc. (NUTX) key facts

Strength: Nutex Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $875.3 million, up 82.4% from fiscal 2024.
Nutex Health Inc. (NUTX) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NUTX traded at $185.95, a market capitalization of $1.4 billion.
Return on equity was 23.1% and debt-to-equity 0.59.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.27 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.